Skip to main content
Equibles
NVCT logo

NVCT · Nuvectis Pharma, Inc.

Track NVCT — free

Use NVCT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NVCT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$23.99 +1.50 (+6.67%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$781.63M
Shares
32.58M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$23.99 Open$22.96 Day$22.28–24.24 52W close$5.65–28.53 Avg vol 30d202K Short int2.2M · 6.7% float · 9.3d Short vol60% Last earningsJun 22, 2026 DataFeb 2022–Sep 2026 Filing10-Q · Aug 4

Up next

Latest filing: 10-Q
filed Aug 4, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$27.85M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$22.16M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+9.9%
Year over year · more shares
Price change (1Y)
+258.1%
Trailing year
Short interest
6.7%
Latest settlement · 9.3 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Neutral Momentum Very Strong Sentiment Bullish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +94%
above
Price vs 50-day avg +14%
above
RSI (14) 57
neutral
MACD trend Negative
52-week position 80%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +25%
trailing
6-month return +191%
trailing
YTD return +218%
this year
Relative strength +174%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $21 › 200d $12 — 50d above 200d
Institutional flow Accumulating
+32% holders QoQ · +29 funds added
Insider flow Accumulating
Net +$1.2M over 90 days · 0% sells
Short interest Rising
6.74% of float · ▲ +19.6% MoM · 9.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
83 holders — near 3-yr high, broad support
Squeeze score 85
high risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 83%
annualized · 1-yr
Max drawdown −37%
past year
ATR 6.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+94% Bullish
Price vs 50-day avg
+14% Bullish
RSI (14)
57 Neutral
MACD trend
Negative Bearish
52-week position
80% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $21 › 200d $12 — 50d above 200d
Institutional flow Accumulating
+32% holders QoQ · +29 funds added
Insider flow Accumulating
Net +$1.2M over 90 days · 0% sells
Short interest Rising
6.74% of float · ▲ +19.6% MoM · 9.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
83 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $6 Now $24 · 80% Range high $29
vs 200-day avg +94% vs 50-day avg +14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NVCT
Nuvectis Pharma, Inc.
this stock
$781.63M +217.7% — — 6.7%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.40B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.60B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
83
% held
32.7%
Net QoQ
+6.1M sh
Top holder
TANG CAPITAL MANAGEMENT L…
Held Float
View
Held by Funds
Fund positions
73
View
Short & Settlement
Short Interest Rising
Shares short
2.2M
Days to cover
9.3d
Change
+359.8K sh
View
Short Volume
Short vol %
60%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
5.5K
Value
$103.8K
As of
Aug 10, 2026
View
Off-Exchange
Off-exchange %
37.5%
Week of
Aug 3, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$1.2M
Buyers / Sellers
2 / 0
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-26.4M
EPS diluted
$-1.32
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 21, 2026
This year
14
View
Exempt Offerings
Offering
$15.9M
Filed
Aug 10, 2022
View
Earnings & Events
Earnings Calls
Last call
Sep 11, 2026
View

Performance

5D 20D 120D MTD YTD
NVCT -1.6% +24.8% +191.5% +5.5% +217.8%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -0.4% +26.5% +173.7% +5.9% +205.7%
Key facts CIK 1875558 CUSIP 67080T108 13F (30d) 45 filings 45 filers Visit website Investor relations